# Debate Matchup Judgment Report

**Grok 4.5 (high)** vs **Kimi K3**

- Paired result: **Kimi K3**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Open-source hardware designs for medical devices would save more lives in low-income countries than traditional IP-protected development pipelines.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0482__grok-4.5-high__kimi-k3__s0__tpl_placement_active_20260320f.md): PRO = **Grok 4.5 (high)**, CON = **Kimi K3**
- [Debate B transcript](../../../transcripts/prop_0482__kimi-k3__grok-4.5-high__s1__tpl_placement_active_20260320f.md): PRO = **Kimi K3**, CON = **Grok 4.5 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_20260902_finala.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0482__grok-4.5-high__kimi-k3__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Grok 4.5 (high)**, CON = **Kimi K3**
- Judged result: Unanimous `3-0` for **Kimi K3**.
- Entertainment scores: `7`, `8`, `7`
- Mean signed raw margin (PRO+): `-2.53`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Kimi K3 (CON); B = Grok 4.5 (high) (PRO) | Kimi K3 | -2.6 | -2.53 | 7.0 |
| GPT-5.6 Sol (high) | A = Kimi K3 (CON); B = Grok 4.5 (high) (PRO) | Kimi K3 | -2.5 | -2.36 | 7.0 |
| Gemini 3.1 Pro Preview | A = Grok 4.5 (high) (PRO); B = Kimi K3 (CON) | Kimi K3 | -2.5 | -2.12 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Kimi K3 (CON); B = Grok 4.5 (high) (PRO)): CON (A) built and sustained a clear analytical framework—lives saved = units delivered × functioning fraction × net benefit per use—that let it concede PRO's volume advantage while showing why validation and maintenance capacity determine the other two factors. CON's pressure question ("who validates, who is accountable") exposed a real gap, and PRO's answer ("published test protocols," "accountability sits with deployers") was vague and was effectively dismantled in the next round as "guesswork with paperwork." PRO's own pressure question ("what functioning rate would still net fewer lives") was answered head-on rather than dodged, with CON reframing why no single rate resolves the issue since per-use value can be negative, not just zero. PRO's case increasingly leaned on a "permanent zero" framing for the lowest-margin wards, but CON directly rebutted this by pointing to tiered pricing, pooled procurement, and licensed local manufacture already reaching poor clinics—a rebuttal PRO's closing never squarely answered, instead reasserting the zero-baseline claim. CON's closing crystallized the clash cleanly and turned PRO's "no diversion where nothing exists" argument backwards by noting false reassurance misdirects resources the ward does have. Overall CON provided the more rigorous, better-defended comparative path to the motion's actual question.
  Most decisive rebuttal noted: A's Rebuttal 2 (A4.1-A4.4) directly dismantling PRO's "permanent zero" premise and exposing "published test protocols" as unaccountable guesswork was the most decisive exchange, since PRO's closing never recovered from it.
- **GPT-5.6 Sol (high)** (A = Kimi K3 (CON); B = Grok 4.5 (high) (PRO)): Side A won by separating device volume from functioning rate and net benefit per use, then showing that validation, calibration, maintenance, traceability, and recalls are necessary to turn designs into lives saved. Side B relied too heavily on an asserted baseline of permanent zero and treated published protocols and public fixes as substitutes for calibrated instruments and physical recall capacity. It also largely accepted A's framing of open hardware as locally fabricated makerspace equipment rather than establishing a safer open-development model.
  Most decisive rebuttal noted: Side A's decisive response was that a versioned repository is not a recall system and a published protocol is not a calibrated reference instrument. This directly undermined Side B's claim that openness itself supplies validation, accountability, and reliable local maintenance.
- **Gemini 3.1 Pro Preview** (A = Grok 4.5 (high) (PRO); B = Kimi K3 (CON)): Side B won by successfully reframing the debate around safety, validation, and net benefit per use. Side B systematically dismantled Side A's premise that 'something is better than nothing' by demonstrating how unvalidated devices have negative utility by misdirecting scarce resources. Side B also cleanly neutralized Side A's defense of open-source validation and accountability.
  Most decisive rebuttal noted: Side B's Rebuttal 2 and Closing exposed the flaw in Side A's validation defense, noting that a published protocol without calibrated instruments is 'guesswork with paperwork,' and that a faulty oximeter misdirects the nurse and oxygen the ward *does* have.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0482__kimi-k3__grok-4.5-high__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Kimi K3**, CON = **Grok 4.5 (high)**
- Judged result: Unanimous `3-0` for **Kimi K3**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `+2.03`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Grok 4.5 (high) (CON); B = Kimi K3 (PRO) | Kimi K3 | +2.2 | +2.14 | 7.0 |
| GPT-5.6 Sol (high) | A = Grok 4.5 (high) (CON); B = Kimi K3 (PRO) | Kimi K3 | +1.7 | +1.61 | 8.0 |
| Gemini 3.1 Pro Preview | A = Kimi K3 (PRO); B = Grok 4.5 (high) (CON) | Kimi K3 | +2.2 | +1.87 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Grok 4.5 (high) (CON); B = Kimi K3 (PRO)): B built a consistent counterfactual frame ("open device vs. nothing, and nothing has a mortality rate") and a stable weighing formula (performance × deployment × years-in-service) that it applied throughout, sharpening rather than widening the clash. Its pressure questions on financing exposed a real tension in A's case, and A's answer—that donors, ministries, and public procurement already deliver validated hardware, with logistics/power gaps explaining empty wards—effectively conceded that public money, not patent rents, is the operative payer in these settings. B seized this in Rebuttal 2 and Closing, arguing this collapses A's liability/brand-discipline mechanism (which A conceded doesn't reach Lilongwe) and converts the debate into "what should the public payer fund." A's counter that upstream export-market brand discipline cross-subsidizes donated units is plausible but underdeveloped and asserted late, and A's closing reasserts prior claims rather than resolving this specific tension. A's strongest material—equipment graveyards, false-confidence risk from drift—was met head-on by B (graveyards are proprietary black boxes; drift also occurs in proprietary devices; unmonitored hypoxemia kills at the full untreated rate), and A never fully neutralized these responses. Both sides handled the Pressure Questions format correctly, but B's answers did more actual work advancing its case, while A's answers mostly reasserted existing claims without fully closing the gap B exposed.
  Most decisive rebuttal noted: B's Rebuttal 2 (A1) turning A's own concession that "public programs and transfers already deliver" into proof that public money, not patent exclusivity, is the real payer—undercutting A's liability/brand-discipline mechanism and reframing the entire debate around what that public money should fund.
- **GPT-5.6 Sol (high)** (A = Grok 4.5 (high) (CON); B = Kimi K3 (PRO)): Side B won by showing that openness need not sacrifice validation while directly improving affordability, adaptation, repairability, and years in service. Side A persuasively identified risks from local variants and weak quality control, but repeatedly treated open designs as inherently unvalidated sketches and never established that IP exclusivity was necessary for testing. B's public financing model and deployment-focused weighing therefore remained a live, clearer route to more lives saved, although its claims that proprietary devices deliver effectively nothing were overstated.
  Most decisive rebuttal noted: B's strongest exchange was its answer to the funding challenge: donors and ministries already finance procurement, so they can finance validation once and release the results as a public good. This undercut A's core equation of openness with skipped testing, while A's response about repeated certification for local forks limited but did not defeat that argument.
- **Gemini 3.1 Pro Preview** (A = Kimi K3 (PRO); B = Grok 4.5 (high) (CON)): Side A won by effectively controlling the comparative and turning Side B's strongest attacks. Side A successfully argued that equipment graveyards are a symptom of IP-protected sealed designs, and cleanly answered the validation burden by pointing out that public money already pays for deployment and can simply fund bench testing for open designs as a public good.
  Most decisive rebuttal noted: Side A's second rebuttal (A4) dismantled Side B's pressure questions by distinguishing the cost of bench-testing an oximeter from a drug trial, and by explaining that open source publishes the very calibration procedures needed to prevent the dangerous "drift" Side B warned about.

## Technical metadata

- Evaluation scope: `judge_judge_blend_20260902_finala__debate_all_templates`
- Topic ID: `prop_0482`
- Side-swap group ID: `prop_0482__grok-4.5-high__kimi-k3__tpl_placement_active_20260320f`
- Raw paired winner: **Kimi K3**
- Mean normalized margin for Grok 4.5 (high): `-2.10`
- Complete side swap: `yes`
- Included in ratings: `yes`
